54.98
-0.59(-1.06%)
Currency In USD
| Previous Close | 55.57 |
| Open | 55.65 |
| Day High | 56.44 |
| Day Low | 54.87 |
| 52-Week High | 86.68 |
| 52-Week Low | 27.66 |
| Volume | 716,834 |
| Average Volume | 1.48M |
| Market Cap | 7.8B |
| PE | -11.34 |
| EPS | -4.85 |
| Moving Average 50 Days | 48.33 |
| Moving Average 200 Days | 39.16 |
| Change | -0.59 |
If you invested $1000 in Vaxcyte, Inc. (PCVX) since IPO date, it would be worth $2,102.49 as of February 11, 2026 at a share price of $54.98. Whereas If you bought $1000 worth of Vaxcyte, Inc. (PCVX) shares 5 years ago, it would be worth $2,126.06 as of February 11, 2026 at a share price of $54.98.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Vaxcyte to Report Fourth Quarter and Full Year 2025 Financial Results and Provide Business Update on February 24, 2026
GlobeNewswire Inc.
3 hours ago
SAN CARLOS, Calif., Feb. 10, 2026 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (Nasdaq: PCVX), a clinical-stage vaccine innovation company, announced today that it will report financial results for the fourth quarter and full year 2025 and provide a business
Vaxcyte to Present at the Guggenheim Emerging Outlook: Biotech Summit
GlobeNewswire Inc.
Feb 05, 2026 9:05 PM GMT
SAN CARLOS, Calif., Feb. 05, 2026 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (Nasdaq: PCVX), a clinical-stage vaccine innovation company, today announced that Company management will participate in a fireside chat at the Guggenheim Emerging Outlook: Biotech
Vaxcyte Announces Closing of $632.5 Million Public Offering Including Full Exercise of Underwriters’ Option to Purchase Additional Shares
GlobeNewswire Inc.
Feb 02, 2026 9:05 PM GMT
SAN CARLOS, Calif., Feb. 02, 2026 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (Nasdaq: PCVX), a clinical-stage vaccine innovation company, announced today the closing of its previously announced underwritten public offering of 12,650,000 shares of common sto